Zyn vs. Snus

Nicotine pouches and Swedish snus look similar, sit in the same part of the mouth, and deliver nicotine through the same tissue. The difference that matters most is what is inside the pouch, and the consequences of that difference ripple through the toxicology, the regulatory status, the available evidence, and the inferences we can draw about long-term risk.

What is in each product

Swedish snus is ground, pasteurized tobacco packed into a porous pouch. The pasteurization (heat treatment rather than fermentation) distinguishes it from American dip and chewing tobacco, which undergo fermentation that produces higher levels of some carcinogens. Snus contains nicotine bound within the tobacco leaf, along with the full complement of tobacco-derived compounds, including tobacco-specific nitrosamines (TSNAs). It also contains the thousands of other compounds present in processed tobacco: polycyclic aromatic hydrocarbons, certain heavy metals absorbed by the tobacco plant from soil, and various organic compounds that result from the curing and processing of the leaf.

The pasteurization step is significant. By heat-treating the tobacco rather than fermenting it, Swedish snus manufacturers produce a product with substantially lower TSNA levels than American smokeless tobacco products. This processing difference is one of the reasons that the Swedish epidemiological data on snus is more favorable than the data on American smokeless products, and it is why “smokeless tobacco” is not a useful single category for risk assessment.

Nicotine pouches (Zyn, On, Velo, and others) contain no tobacco leaf. The nicotine is either extracted from tobacco or synthesized, then mixed with a cellulose filler, flavorings, sweeteners, and pH adjusters (typically sodium carbonate or a similar alkaline compound). The absence of tobacco leaf means substantially lower TSNA levels [2]. It also means the absence of the other tobacco-derived compounds mentioned above.

The filler material in nicotine pouches is plant-derived cellulose, which is biologically inert. The pH adjusters serve the same function as those in snus: they create an alkaline environment that converts nicotine to its freebase form for efficient mucosal absorption. The flavorings and sweeteners are food-grade additives, though their long-term safety profile when held against oral tissue for extended periods is not specifically established.

Nicotine delivery

A pharmacokinetic study comparing nicotine pouches and snus found that both deliver nicotine through the oral mucosa at comparable rates and to comparable peak plasma levels when matched for nicotine content [3]. The absorption mechanism is the same: the alkaline pH converts nicotine to its freebase form, which crosses the mucosal membrane into the capillary blood supply.

The time to peak plasma nicotine concentration is similar between the two products, typically 20 to 30 minutes. The subjective nicotine satisfaction reported by users is also comparable [3]. Users switching between the two typically find the nicotine delivery similar, with differences in flavor, mouthfeel, and the sensation of having tobacco material versus cellulose against the gum.

There are some differences in the delivery curves. Snus portions tend to release nicotine somewhat more gradually because the nicotine is bound within the tobacco matrix and must be extracted before it can be absorbed. Nicotine pouches release the nicotine more directly, because it is already in a dissolved or readily soluble form within the filler. In practice, these differences are small enough that users of comparable-strength products report similar experiences.

The labeled nicotine content is not a reliable guide to the absorbed dose. Absorption efficiency depends on pH, contact area, moisture content, and how long the pouch remains in place. A snus portion labeled at 8mg may deliver a similar absorbed dose to a nicotine pouch labeled at 6mg, depending on the formulation of each.

The toxicant difference

The critical difference is TSNA exposure. An independent analysis found that nicotine pouches contain TSNAs at levels 95% to 99% lower than Swedish snus, which itself contains TSNAs at levels far below those of American smokeless tobacco [2] [5]. The near-elimination of TSNAs is a direct consequence of removing the tobacco leaf from the product.

TSNAs, particularly NNK (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) and NNN (N’-nitrosonornicotine), are established carcinogens. They are formed during the processing of tobacco and are the primary chemical link between smokeless tobacco use and cancer risk. NNK is the most potent of the group and has been shown to cause lung, oral, and pancreatic tumors in animal models. The reduction in TSNA exposure from snus to nicotine pouches is not a small improvement on a continuum; it is the near-elimination of the most clearly identified carcinogenic compounds in oral nicotine products.

Other toxicants present in snus but absent or minimal in nicotine pouches include polycyclic aromatic hydrocarbons, heavy metals (cadmium, lead, arsenic at trace levels), and some volatile organic compounds that occur naturally in tobacco leaf or are produced during processing [5]. Whether these compounds, at the levels present in snus, contribute meaningfully to health risk is debated. Their near-absence in nicotine pouches removes the question.

The funding of the compositional analyses is worth noting. The Azzopardi et al. study was funded by BAT (British American Tobacco), which manufactures nicotine pouches [5]. The Stepanov et al. TSNA comparison was independent, conducted at the University of Minnesota [2]. The direction of the findings is consistent across both funded and independent analyses, which increases confidence in the compositional data, but the industry’s financial interest in demonstrating favorable toxicant profiles for their products is a standing consideration.

What the snus data tells us

Swedish snus has the most extensive safety data of any oral nicotine product. Large prospective cohort studies, following over 100,000 Swedish men for decades, have found [1] [4]:

• No increase in lung cancer risk (expected, as there is no smoke)
• No increase in oral cancer risk (the pasteurization and lower TSNA content compared to fermented tobacco likely explain this)
• A small, inconsistent increase in cardiovascular risk, primarily in the period following a myocardial infarction
• A possible modest increase in pancreatic cancer risk, though the data is mixed and confounding is difficult to eliminate
• Oral mucosal changes at the habitual placement site, which are common but generally considered benign

The overall mortality risk for snus users is far lower than for cigarette smokers and is not clearly distinguishable from that of non-tobacco users in most analyses [6]. The Royal College of Physicians, in an independent review of the evidence, placed snus among the lowest-risk nicotine products available, substantially below cigarettes and comparable to long-term NRT use in its overall health impact.

The Swedish data is unusually strong because of Sweden’s unique tobacco history. A large male population has used snus as a primary tobacco product for generations, providing the kind of long-term, large-sample epidemiological data that is rarely available for consumer products. The prospective cohort designs, following people forward in time rather than looking backward, reduce many of the biases that weaken observational studies.

What this means for pouches

If snus, which contains actual tobacco, shows minimal long-term health risk in decades of cohort data, it is reasonable to expect that nicotine pouches, which contain substantially less of the toxicants present in snus, would carry equal or lower risk.

This is a reasonable inference, not a proven conclusion. The inference is strong for cancer risk, where the relevant toxicants (TSNAs) are measurably lower in pouches. The logic is direct: the carcinogenic compounds are nearly absent, so the carcinogenic risk should be at least as low as snus, where it is already very low.

The inference is weaker for cardiovascular risk, where nicotine itself, present in both products at comparable doses, is the primary mechanism. The snus cardiovascular data shows a small, inconsistent signal, and that signal is driven by nicotine’s hemodynamic effects rather than by tobacco-specific toxicants. Since pouches deliver comparable nicotine, there is no reason to expect their cardiovascular risk profile to be lower than that of snus.

And the inference does not address unknown risks that might emerge from long-term exposure to the specific excipients and pH adjusters used in nicotine pouches, which are different from those in snus. The cellulose filler, the specific pH adjusters, and the flavoring compounds have not been studied for the effects of chronic oral mucosal contact over years. They are generally recognized as safe food-grade ingredients, but that recognition does not specifically cover the use case of holding them against gum tissue for hours per day, year after year.

The regulatory asymmetry

Swedish snus occupies a peculiar position in the regulatory landscape. It is banned for sale in the European Union (except Sweden, which negotiated an exemption upon joining), but it has the strongest safety data of any smokeless tobacco product. Nicotine pouches, which contain no tobacco, are not subject to the EU snus ban and are sold across Europe. In the United States, both products are legal, but snus is regulated as a smokeless tobacco product while nicotine pouches are regulated either as tobacco products (for those using tobacco-derived nicotine) or under newer provisions for synthetic nicotine.

No nicotine pouch has received modified risk tobacco product (MRTP) authorization from the FDA, which would require the manufacturer to demonstrate, with product-specific evidence, that the product reduces risk relative to cigarettes. Several snus products have received this authorization. This creates a situation where the product with more safety data (snus) has the regulatory endorsement, while the product that is likely lower-risk on compositional grounds (pouches) does not, because the product-specific evidence base is not yet mature enough to support the application.

What remains unknown

Whether the lower TSNA exposure of nicotine pouches translates to measurably lower cancer risk compared to snus, given that snus cancer risk is already very low. Whether the excipients in nicotine pouches (cellulose fillers, pH adjusters, flavorings) produce any long-term effects that are not present with snus. Whether the oral tissue effects of pouches and snus differ meaningfully over years of use. Whether the different use patterns (pouches are used more continuously by some users, and the user population skews younger) alter the risk profile beyond what the toxicant comparison would predict. And whether the inference from snus safety data to pouch safety is as straightforward as the compositional data suggests, or whether long-term pouch-specific studies will reveal differences that the current evidence cannot anticipate.

If you have questions about nicotine use and your health, speak with a doctor or pharmacist. The Quitline (1-800-QUIT-NOW) can help with quitting strategies.